ArticleAntimicrobial agents and chemotherapy2018
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Pooled it
- Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Challenges in ITS-based identification ofMicrobiology spectrum · 2026Article
- Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Safety and efficacy of echinocandin antifungal agents inAntimicrobial agents and chemotherapy · 2026Article
- Neutralizing GM-CSF autoantibodies impair neutrophil antifungal effector function in a patient with aspergillosis.The Journal of infection · 2025Article
- Insights from Mass Spectrometry-Based Proteomics onJournal of fungi (Basel, Switzerland) · 2025Review
- Antifungal Minimal Inhibitory Concentrations of Mold Isolates from Patients with Cancer; Single-Center Experience, 2018-2023.Journal of fungi (Basel, Switzerland) · 2025Article
- Single-Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs.Journal of veterinary pharmacology and therapeutics · 2025Article
- Review
- Use of voriconazole to predict susceptibility and resistance to isavuconazole forJournal of clinical microbiology · 2025Article
- High azole MICs in Fusarium spp.: a key factor in treatment decisions for cancer patients?Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- TheIranian journal of pathology · 2025Article
- First Report ofInfection and drug resistance · 2025Article
- Evaluation of the Activity of Triazoles Against Non-Open forum infectious diseases · 2024Article
- Trends in the activity of mold-active azole agents againstJournal of clinical microbiology · 2024Article
- Article
- Antifungal susceptibility testing following the CLSI M27 document, along with the measurement of MFC/MIC ratio, could be the optimal approach to detect amphotericin B resistance inAntimicrobial agents and chemotherapy · 2024Article
- Fungi involved in rhinosinusitis in arid regions: insights from molecular identification and antifungal susceptibility.Microbiology spectrum · 2023Article
- In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales.Pathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring antifungal susceptibility patterns for new and established antifungal agents seems prudent given the increasing prevalence of uncommon species associated with higher antifungal resistance. We evaluated the activity of isavuconazole against 4,856 invasive yeasts and molds collected worldwide. The 4,856 clinical fungal isolates, including 2,351
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.